The Means, the Mission, and the Pledge of <i>The Oncologist</i>

We are pleased to welcome Gabriel N. Hortobágyi, M.D., F.A.C.P. as a Senior Editor of The Oncologist. Dr. Hortobágyi chairs the Department of Breast Medical Oncology and directs the Breast Cancer Research Program at The University of Texas M.D. Anderson Cancer Center, where he holds the Nellie B. Connally Chair in Breast Cancer. One of the world's leading authorities on the use of chemotherapy for breast cancer, he is widely known for a landmark studies he initiated as a member of the M.D. Anderson where he has served on faculty since 1976. Dr. Hortobágyi has been instrumental in developing combination chemotherapy for previously inoperable breast tumors and for improving multidisciplinary treatment for patients with all stages of breast cancer, including advanced disease. He served as a member of the U.S. National Committee for the International Union Against Cancer (1997–2001), and the National Cancer Institute's Breast Cancer Progress Review Group (1997). Dr. Hortobágyi chairs the Health Advisory Board of the Susan G. Komen Breast Cancer Foundation, and was a member of the Integration Panel of the Breast Cancer Research Program of the Department of Defense (1998–2001). He is currently a member of the Medical Advisory Board of the Breast Cancer Research Foundation. Among major honors for his breast cancer research, Dr. Hortobágyi has received the 1995 Cino del Duca Award, the 1997 Brinker International Award for Clinical Research, the medal of the Japanese Surgical Society (1997), and the Sir Peter Freyer Medal in Galway, Ireland. In 1999 he received the Vermeille Medal from the City of Paris, and in 2001 President Jacques Chirac named him Chevalier of la Legion d'Honneur de France. Gabriel N. Hortobágyi, M.D., F.A.C.P. We also acknowledge our gratitude to Dr. Raphael E. Pollock for his role in helping to develop, in collaboration with Dr. John E. Niederhuber, the surgical oncology section of The Oncologist. As Raph now retires from the rigorous duties of Senior Editor we are grateful that his guidance will not be lost since he remains on our Editorial Board. In just eight years, The Oncologist has become one of the most important physician-reviewed providers of relevant cancer medicine information. In fact, The Oncologist has become one of the world's most widely read cancer journals with more than 21,500 readers of its US and European print editions. More than 180,000 readers visit The Oncologist online (www.TheOncologist.com) monthly, and more than 30,000 physicians and other health care providers visit The Oncologist's online Continuing Medical Education website (www.CME.TheOncologist.com) on a monthly basis. The prominence of The Oncologist is, of course, the result of many factors, among them the mission to bring relevant information on the multimodality practice of oncology to practitioners who are community based. Papers are, therefore, carefully selected and edited to provide you, our readers, with perspectives that are authoritative and relevant. The selection of these papers, in fact, the entire tone and tempo of the Journal are set and carefully maintained by our Editorial Board. As Editors, we are pleased to welcome the following new members to The Oncologist's Editorial Board: Stan Kaye, Royal Marsden Hospital; Peter Kozuch, Roosevelt Hospital; and Jeffrey Supko, Massachusetts General Hospital, as well as the following new Section Editors: Acute and Chronic Leukemias and Multiple Myeloma, Bob Löwenberg, University Hospital Rotterdam; Cancer Imaging, Gregory Sorensen, Harvard Medical School; Clinical Genetics and Genetic Counseling, Ilan R. Kirsch, National Institutes of Health, National Cancer Institute; Epidemiology, Access, and Outcomes, Peter Boyle, International Agency for Research on Cancer; Gastrointestinal Cancer, Peter J. O'Dwyer, University of Pennsylvania; Geriatric Oncology, Matti S. Aapro, Multidisciplinary Oncology Institute and Michele Evans, National Institute on Aging; Immunotherapy, Monoclonals, and Vaccines, Michael T. Lotze, Translational Research Molecular Medicine Institute University of Pittsburgh; Medical Ethics, Gerd Richter, University Marburg; Melanoma and Cutaneous Malignancies, Alexander M.M. Eggermont, Erasmus Medical Center; Neuro-Oncology, Charles J. Vecht, Medical Center The Hague; and Sarcomas, Jaap Verweij, Erasmus Medical Center. We gratefully acknowledge those who have concluded their term of service on the editorial board: Ross C. Donehower, Johns Hopkins Oncology Center; Timothy J. Eberlein, Alvin J. Siteman Cancer Center; Lyonel G. Israels, University of Manitoba; William A. Nahhas, Wright State University; Peter W. Pisters, University of Texas M.D. Anderson Cancer Center; Peter E. Schwartz, Yale University School of Medicine; Lars-Erik Tisell, Sahlgrenska University Hospital; and Stanley H. Winokur, Network for Oncology Communication and Research. This past year we significantly increased the utility and education impact through The Oncologist CME Online. We are proud to be the first and only journal whose online category 1 CME accreditation is approved by the National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES). Provided as a free service to all registered users, The Oncologist CME Online covers all aspects of oncology medicine, including courses in Risk Management, important in quality practice and patient care, but very often difficult credits to obtain in the busy clinical setting. Each issue contains articles providing 10 to 12 hours of new AMA/PRA category 1 credit. We continually welcome feedback from you on ways to better meet your educational needs. Always striving to report on current controversies in a fair and balanced fashion, we continue to seek what is new and important, recruiting key opinion leaders to author manuscripts for peer-reviewed publication consideration. Keeping the Journal on course, not allowing it to stray from the mission upon which we originally embarked, we have focused on key topics that warrant coverage in greater depth. Three new Journal supplements have recently been published to widespread acclaim: Penetrating Insights: Crossing the Cancer Cell Membrane to Improve Clinical Outcomes The Oncologist 8 (suppl 3):1S–45S. Liposomal Anthracyclines for Breast Cancer: Clinical Efficacy and Safety Update The Oncologist 8 (suppl 2):1S–30S. Cancer Fatigue: The Way Forward The Oncologist 8 (suppl 1):1S–33S. We welcome your recommendations for future topics, and we encourage you to share your suggestions on other subjects of importance to you and your care for your cancer patients. Our greatest appreciation is reserved for cancer patients and for you, our readers. It is, after all, to them and for you that we dedicate ourselves and The Oncologist. We wish you a healthy and happy New Year …and pledge that in this, The Oncologist's ninth year, we will continue to bring you the best cancer medicine literature possible.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.